TONGJITANG CHINESE MEDICINES

They are a vertically integrated and profitable specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine. They believe that their flagship product, Xianling Gubao, is the leading traditional Chinese medicine for the treatment of osteoporosis in China as measured by sales in Renminbi amounts, according to a May 2006 report commissioned by them and prepared by China Southern Medicine Economy Research Institute, or... SMERI, which is a research institute affiliated with the China State Food and Drug Administration, or the SFDA. Their product portfolio consists primarily of Xianling Gubao and three other SFDA-approved modernized traditional Chinese medicines designed to address large market opportunities. Their product development pipeline includes potential expanded uses of their existing products for additional medical indications and a number of new product candidates that are intended to address significant medical needs in China, primarily in the therapeutic areas of women’s health, mental health and dermatology.More